BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more
Subscribe to Directory
Write an Article

Highlight

3i closes second European CLO, Harvest V...

by 3i Group

3i Group plc (“3i” or “3i Group”), an international investor, ...

Fundación Bankinter: Emprendimiento soc...

by Fundación Bankinter

El emprendimiento social va más allá de las personas y engloba tambi...

Photos Stream